Evaluation of the efficacy of Chinese herbal medicine Rhizoma arisaemetis preparata in the treatment of high-risk HPV persistent infection in female by transvaginal administration

Evaluation of the efficacy of Chinese herbal medicine Rhizoma arisaemetis preparata in the treatment of high-risk HPV persistent infection by transvaginal administration

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033543

Enrollment

Unknown

Registered

2020-06-05

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection in female genital tract

Interventions

Control group:Nil

Low concentration group of Rhizoma arisaemetis Preparata:Rhizoma arisaemetis Preparata 1g p.v. q.o.d.* 20 days, 10 days off, *3 months

Medium concentration group of Rhizoma arisaemetis Preparata:Rhizoma arisaemetis Preparata 1.5g p.v. q.o.d.* 20 days, 10 days off, *3 months

High concentration group of Rhizoma arisaemetis Preparata:Rhizoma arisaemetis Preparata 2g p.v. q.o.d.* 20 days, 10 days off, *3 months

Baofukang suppository group:Baofukang suppository 1dose p.v. qd.* 7 days, 21 days off, *3 months

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The patient whose high-risk HPV screening result was positive,while after treatment, the review result was still the same type of high-risk HPV.

Exclusion criteria

Exclusion criteria: 1. Patients who was pregnancy, delivery or abortion within 4 weeks, gestational trophoblastic disease; 2. Patients who used other vaginal preparations or lotions within 6 weeks before entering the clinical trial; 3. Patients who had taken antiviral drugs orally within 6 weeks before entering the clinical trial; 4. At present, there are other types of malignant tumor, or other malignant tumor recurrence can not be excluded; 5. Acute phase of other diseases: disturbance of consciousness, body temperature greater than 38 degrees C vital signs instability or acute abdomen, etc.; 6. Significant organ dysfunction: liver enzyme > 5 times normal upper limit, creatinine > 3 times normal upper limit, blood amylase > 2 times normal upper limit, cardiac function 3-4 grade, etc.; 7. Mental illness patients receiving medication. 8. Eliminate trichomonas, mold, Neisseria gonorrhoeae, chlamydia, mycoplasma any kind of infection.

Design outcomes

Primary

Measure	Time frame
high-risk HPV;TCT (LCT);Vaginal secretions routine;	—

Countries

China

Contacts

Public ContactMingzhi Zhao

Obstetrics and Gynecology Hospital of Fudan University

zhaomingzhi1533@fckyy.org.cn+86 13585929498

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026